BioSpace News Archive

Pacylex Pharmaceuticals, an oncology company developing a first-in-class, oral drug for a new approach to cancer therapy, today announced the publication in the journal Current Oncology of data from the first patient.

Shanghai Junshi Biosciences Co., and Coherus Biosciences today announced the presentation of positive results and biomarker analyses from the pivotal study “CHOICE-01” (clinicaltrials.gov identifier# NCT03856411).

Today, Trevi announced that it concluded enrollment early for its Phase 2 Cough And NALbuphine (CANAL) trial for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) patients following the previously announced statistically significant efficacy results from the interim analysis (N=26).

LimFlow SA, a pioneer in the development of minimally-invasive technology for the treatment of chronic limb-threatening ischemia (CLTI), a severe form of peripheral artery disease (PAD), announced today that it has completed patient enrollment in the PROMISE II pivotal trial of the LimFlow System.

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has filed an application for clearance to initiate a Phase 1/2a clinical trial of ARO-RAGE.

Werewolf Therapeutics, Inc. announced the publication of two abstracts summarizing upcoming poster presentations at the American Association for Cancer Research Annual Meeting.

Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a biotechnology company transforming the drug discovery paradigm with structurally targeted allosteric regulators (STARs) identified with its proprietary computational discovery platform, today presented new pre-clinical data from its Parkinson’s and Alzheimer’s Disease programs.

Microbion Corporation today announced that the US Patent and Trademark Office (USPTO) issued United States Patent No. 11,207,288 to Microbion on December 28, 2021, with claims to the use of Microbion’s proprietary pravibismane topical composition for diabetic foot infections (“DFI”).

Sonendo, Inc., a dental technology company and creator of the GentleWave System for less invasive and less painful root canal therapy, announced its achievement of a new milestone of 800,000 GentleWave patient procedures.

Johnson & Johnson will host a conference call for investors at 8:30 a.m. on Tuesday, April 19th to review first-quarter results.